Cancer Epidemiology, Biomarkers & Prevention:“夜班族”注意了!研究证实:长期夜班增加女性患癌风险!

2018-01-15 佚名 生物探索

导读:对“夜班族”来说,这不是一个好消息——来自四川大学华西医院的一个研究小组在最新发表的一项研究中称,女性长期夜班工作会使患癌风险增加19%。具体来说,患皮肤癌、乳腺癌和胃肠道癌症的风险分别会增加41%、32%和18%。1月7日,发表在Cancer Epidemiology, Biomarkers & Prevention上的这项研究中,科学家们利用来自61篇文章的数据进行了荟萃分析,共

导读:对“夜班族”来说,这不是一个好消息——来自四川大学华西医院的一个研究小组在最新发表的一项研究中称,女性长期夜班工作会使患癌风险增加19%。具体来说,患皮肤癌、乳腺癌和胃肠道癌症的风险分别会增加41%、32%和18%。

1月7日,发表在Cancer Epidemiology, Biomarkers & Prevention上的这项研究中,科学家们利用来自61篇文章的数据进行了荟萃分析,共包含了来自北美、欧洲、澳大利亚和亚洲的3,909,1 52名参与者,其中,癌症病例为114,628例。

这61篇文章包括26个队列研究(cohort studies)、24个病例对照研究(case-control studies)以及11个嵌套病例对照研究(nested case-control studies)。这些研究分析了长期夜班工作与11种癌症风险之间的关联。

患癌风险增加19%

总的来说,女性长期夜班工作会使患癌风险增加19%。对特定的癌种进行分析发现,长期夜班工作的女性患皮肤癌的风险增加41%,患乳腺癌的风险增加32%,患胃肠道癌症的风险增加18%。

不过,根据位置对参与者进行分类后,研究人员发现,乳腺癌风险的增加只发生在来自北美和欧洲的女性夜班工作者中。论文的通讯作者、华西医院主治医师马学磊(Xuelei Ma)博士说:“这一点让我们很惊讶。这可能是因为,这些地区的女性含有较高的性激素水平。”

每5年夜班工作,患乳腺癌风险增加3.3%

此外,如果按照职业进行分类,夜班工作的女护士患乳腺癌的风险增加了58%,患胃肠道癌症的风险增加了35%,患肺癌的风险增加了28%。在所有的职业分析中,上夜班的护士患乳腺癌的风险最高。

另一方面,研究中,科学家们还进行了剂量响应荟萃分析(dose-response meta-analysis)。结果显示,每5年夜班工作(every five years of night shift work),患乳腺癌风险增加3.3%。

意义与局限

研究人员表示,通过整合大量先前的数据发现,夜班工作与女性中多种常见的癌症呈正相关。这些结果表明,长期的女性夜班工作者需要健康保护计划。

马学磊博士说:“鉴于全球范围内轮班工作日益普遍,以及癌症公共负担非常严重,我们发起了这项研究,以引起公众对这一问题的关注。我们希望,学界能开展更多的大型队列研究来证实这些关联。”

不过,这项研究的一个局限性是,纳入荟萃分析的不同研究中对长期夜班工作("long-term" night shift work)的界定缺乏一致性,有的定义为“在夜间工作”(working during the night),有的定义为“每个月至少工作3个晚上”(working at least three nights per month)。

此外,研究人员也强调,这项工作只是对先前研究展开荟萃分析,更准确的结论与机制需进一步研究。男女癌症发病率有很大差异,此项研究只纳入女性群体,后续关于男性群体的研究正在进行中。

原文出处:

Xia Yuan,Chenjing Zhu,Manni Wang,et al. Night Shift Work Increases the Risks of Multiple Primary Cancers in Women: A Systematic Review and Meta-analysis of 61 Articles,Cancer Epidemiology,Biomarkers & Prevention,DOI:10.1158/1055-9965.EPI-17-0221 Published January 2018.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1917873, encodeId=8398191e8738e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 23 01:04:00 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052365, encodeId=8077205236596, content=<a href='/topic/show?id=aeece1137b' target=_blank style='color:#2F92EE;'>#event#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7113, encryptionId=aeece1137b, topicName=event)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu Jun 21 08:04:00 CST 2018, time=2018-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778433, encodeId=18451e784337e, content=<a href='/topic/show?id=1a7c344897' target=_blank style='color:#2F92EE;'>#biomarkers#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3448, encryptionId=1a7c344897, topicName=biomarkers)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=494139226697, createdName=xzw126, createdTime=Tue Oct 09 16:04:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898700, encodeId=1e601898e0056, content=<a href='/topic/show?id=1fa568e6ec' target=_blank style='color:#2F92EE;'>#epidemiology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6876, encryptionId=1fa568e6ec, topicName=epidemiology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sun Mar 11 00:04:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878248, encodeId=737b18e82489e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat May 19 17:04:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907379, encodeId=fb56190e379e3, content=<a href='/topic/show?id=835e11305d7' target=_blank style='color:#2F92EE;'>#marker#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11305, encryptionId=835e11305d7, topicName=marker)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Sun Jun 24 14:04:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061705, encodeId=65092061e0565, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Mar 02 23:04:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007814, encodeId=c019200e81437, content=<a href='/topic/show?id=421d14663a6' target=_blank style='color:#2F92EE;'>#prevention#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14663, encryptionId=421d14663a6, topicName=prevention)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Nov 28 19:04:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413463, encodeId=f38214134636b, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Wed Jan 17 05:04:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601429, encodeId=2c2a16014290c, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Wed Jan 17 05:04:00 CST 2018, time=2018-01-17, status=1, ipAttribution=)]
    2018-04-23 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1917873, encodeId=8398191e8738e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 23 01:04:00 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052365, encodeId=8077205236596, content=<a href='/topic/show?id=aeece1137b' target=_blank style='color:#2F92EE;'>#event#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7113, encryptionId=aeece1137b, topicName=event)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu Jun 21 08:04:00 CST 2018, time=2018-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778433, encodeId=18451e784337e, content=<a href='/topic/show?id=1a7c344897' target=_blank style='color:#2F92EE;'>#biomarkers#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3448, encryptionId=1a7c344897, topicName=biomarkers)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=494139226697, createdName=xzw126, createdTime=Tue Oct 09 16:04:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898700, encodeId=1e601898e0056, content=<a href='/topic/show?id=1fa568e6ec' target=_blank style='color:#2F92EE;'>#epidemiology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6876, encryptionId=1fa568e6ec, topicName=epidemiology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sun Mar 11 00:04:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878248, encodeId=737b18e82489e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat May 19 17:04:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907379, encodeId=fb56190e379e3, content=<a href='/topic/show?id=835e11305d7' target=_blank style='color:#2F92EE;'>#marker#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11305, encryptionId=835e11305d7, topicName=marker)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Sun Jun 24 14:04:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061705, encodeId=65092061e0565, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Mar 02 23:04:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007814, encodeId=c019200e81437, content=<a href='/topic/show?id=421d14663a6' target=_blank style='color:#2F92EE;'>#prevention#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14663, encryptionId=421d14663a6, topicName=prevention)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Nov 28 19:04:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413463, encodeId=f38214134636b, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Wed Jan 17 05:04:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601429, encodeId=2c2a16014290c, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Wed Jan 17 05:04:00 CST 2018, time=2018-01-17, status=1, ipAttribution=)]
    2018-06-21 lhlxtx
  3. [GetPortalCommentsPageByObjectIdResponse(id=1917873, encodeId=8398191e8738e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 23 01:04:00 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052365, encodeId=8077205236596, content=<a href='/topic/show?id=aeece1137b' target=_blank style='color:#2F92EE;'>#event#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7113, encryptionId=aeece1137b, topicName=event)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu Jun 21 08:04:00 CST 2018, time=2018-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778433, encodeId=18451e784337e, content=<a href='/topic/show?id=1a7c344897' target=_blank style='color:#2F92EE;'>#biomarkers#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3448, encryptionId=1a7c344897, topicName=biomarkers)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=494139226697, createdName=xzw126, createdTime=Tue Oct 09 16:04:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898700, encodeId=1e601898e0056, content=<a href='/topic/show?id=1fa568e6ec' target=_blank style='color:#2F92EE;'>#epidemiology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6876, encryptionId=1fa568e6ec, topicName=epidemiology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sun Mar 11 00:04:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878248, encodeId=737b18e82489e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat May 19 17:04:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907379, encodeId=fb56190e379e3, content=<a href='/topic/show?id=835e11305d7' target=_blank style='color:#2F92EE;'>#marker#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11305, encryptionId=835e11305d7, topicName=marker)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Sun Jun 24 14:04:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061705, encodeId=65092061e0565, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Mar 02 23:04:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007814, encodeId=c019200e81437, content=<a href='/topic/show?id=421d14663a6' target=_blank style='color:#2F92EE;'>#prevention#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14663, encryptionId=421d14663a6, topicName=prevention)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Nov 28 19:04:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413463, encodeId=f38214134636b, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Wed Jan 17 05:04:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601429, encodeId=2c2a16014290c, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Wed Jan 17 05:04:00 CST 2018, time=2018-01-17, status=1, ipAttribution=)]
    2018-10-09 xzw126
  4. [GetPortalCommentsPageByObjectIdResponse(id=1917873, encodeId=8398191e8738e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 23 01:04:00 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052365, encodeId=8077205236596, content=<a href='/topic/show?id=aeece1137b' target=_blank style='color:#2F92EE;'>#event#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7113, encryptionId=aeece1137b, topicName=event)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu Jun 21 08:04:00 CST 2018, time=2018-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778433, encodeId=18451e784337e, content=<a href='/topic/show?id=1a7c344897' target=_blank style='color:#2F92EE;'>#biomarkers#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3448, encryptionId=1a7c344897, topicName=biomarkers)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=494139226697, createdName=xzw126, createdTime=Tue Oct 09 16:04:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898700, encodeId=1e601898e0056, content=<a href='/topic/show?id=1fa568e6ec' target=_blank style='color:#2F92EE;'>#epidemiology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6876, encryptionId=1fa568e6ec, topicName=epidemiology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sun Mar 11 00:04:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878248, encodeId=737b18e82489e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat May 19 17:04:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907379, encodeId=fb56190e379e3, content=<a href='/topic/show?id=835e11305d7' target=_blank style='color:#2F92EE;'>#marker#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11305, encryptionId=835e11305d7, topicName=marker)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Sun Jun 24 14:04:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061705, encodeId=65092061e0565, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Mar 02 23:04:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007814, encodeId=c019200e81437, content=<a href='/topic/show?id=421d14663a6' target=_blank style='color:#2F92EE;'>#prevention#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14663, encryptionId=421d14663a6, topicName=prevention)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Nov 28 19:04:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413463, encodeId=f38214134636b, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Wed Jan 17 05:04:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601429, encodeId=2c2a16014290c, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Wed Jan 17 05:04:00 CST 2018, time=2018-01-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1917873, encodeId=8398191e8738e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 23 01:04:00 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052365, encodeId=8077205236596, content=<a href='/topic/show?id=aeece1137b' target=_blank style='color:#2F92EE;'>#event#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7113, encryptionId=aeece1137b, topicName=event)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu Jun 21 08:04:00 CST 2018, time=2018-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778433, encodeId=18451e784337e, content=<a href='/topic/show?id=1a7c344897' target=_blank style='color:#2F92EE;'>#biomarkers#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3448, encryptionId=1a7c344897, topicName=biomarkers)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=494139226697, createdName=xzw126, createdTime=Tue Oct 09 16:04:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898700, encodeId=1e601898e0056, content=<a href='/topic/show?id=1fa568e6ec' target=_blank style='color:#2F92EE;'>#epidemiology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6876, encryptionId=1fa568e6ec, topicName=epidemiology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sun Mar 11 00:04:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878248, encodeId=737b18e82489e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat May 19 17:04:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907379, encodeId=fb56190e379e3, content=<a href='/topic/show?id=835e11305d7' target=_blank style='color:#2F92EE;'>#marker#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11305, encryptionId=835e11305d7, topicName=marker)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Sun Jun 24 14:04:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061705, encodeId=65092061e0565, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Mar 02 23:04:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007814, encodeId=c019200e81437, content=<a href='/topic/show?id=421d14663a6' target=_blank style='color:#2F92EE;'>#prevention#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14663, encryptionId=421d14663a6, topicName=prevention)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Nov 28 19:04:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413463, encodeId=f38214134636b, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Wed Jan 17 05:04:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601429, encodeId=2c2a16014290c, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Wed Jan 17 05:04:00 CST 2018, time=2018-01-17, status=1, ipAttribution=)]
    2018-05-19 anminleiryan
  6. [GetPortalCommentsPageByObjectIdResponse(id=1917873, encodeId=8398191e8738e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 23 01:04:00 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052365, encodeId=8077205236596, content=<a href='/topic/show?id=aeece1137b' target=_blank style='color:#2F92EE;'>#event#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7113, encryptionId=aeece1137b, topicName=event)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu Jun 21 08:04:00 CST 2018, time=2018-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778433, encodeId=18451e784337e, content=<a href='/topic/show?id=1a7c344897' target=_blank style='color:#2F92EE;'>#biomarkers#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3448, encryptionId=1a7c344897, topicName=biomarkers)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=494139226697, createdName=xzw126, createdTime=Tue Oct 09 16:04:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898700, encodeId=1e601898e0056, content=<a href='/topic/show?id=1fa568e6ec' target=_blank style='color:#2F92EE;'>#epidemiology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6876, encryptionId=1fa568e6ec, topicName=epidemiology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sun Mar 11 00:04:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878248, encodeId=737b18e82489e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat May 19 17:04:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907379, encodeId=fb56190e379e3, content=<a href='/topic/show?id=835e11305d7' target=_blank style='color:#2F92EE;'>#marker#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11305, encryptionId=835e11305d7, topicName=marker)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Sun Jun 24 14:04:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061705, encodeId=65092061e0565, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Mar 02 23:04:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007814, encodeId=c019200e81437, content=<a href='/topic/show?id=421d14663a6' target=_blank style='color:#2F92EE;'>#prevention#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14663, encryptionId=421d14663a6, topicName=prevention)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Nov 28 19:04:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413463, encodeId=f38214134636b, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Wed Jan 17 05:04:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601429, encodeId=2c2a16014290c, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Wed Jan 17 05:04:00 CST 2018, time=2018-01-17, status=1, ipAttribution=)]
    2018-06-24 cqlidoudou
  7. [GetPortalCommentsPageByObjectIdResponse(id=1917873, encodeId=8398191e8738e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 23 01:04:00 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052365, encodeId=8077205236596, content=<a href='/topic/show?id=aeece1137b' target=_blank style='color:#2F92EE;'>#event#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7113, encryptionId=aeece1137b, topicName=event)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu Jun 21 08:04:00 CST 2018, time=2018-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778433, encodeId=18451e784337e, content=<a href='/topic/show?id=1a7c344897' target=_blank style='color:#2F92EE;'>#biomarkers#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3448, encryptionId=1a7c344897, topicName=biomarkers)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=494139226697, createdName=xzw126, createdTime=Tue Oct 09 16:04:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898700, encodeId=1e601898e0056, content=<a href='/topic/show?id=1fa568e6ec' target=_blank style='color:#2F92EE;'>#epidemiology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6876, encryptionId=1fa568e6ec, topicName=epidemiology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sun Mar 11 00:04:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878248, encodeId=737b18e82489e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat May 19 17:04:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907379, encodeId=fb56190e379e3, content=<a href='/topic/show?id=835e11305d7' target=_blank style='color:#2F92EE;'>#marker#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11305, encryptionId=835e11305d7, topicName=marker)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Sun Jun 24 14:04:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061705, encodeId=65092061e0565, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Mar 02 23:04:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007814, encodeId=c019200e81437, content=<a href='/topic/show?id=421d14663a6' target=_blank style='color:#2F92EE;'>#prevention#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14663, encryptionId=421d14663a6, topicName=prevention)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Nov 28 19:04:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413463, encodeId=f38214134636b, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Wed Jan 17 05:04:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601429, encodeId=2c2a16014290c, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Wed Jan 17 05:04:00 CST 2018, time=2018-01-17, status=1, ipAttribution=)]
    2018-03-02 sjq027
  8. [GetPortalCommentsPageByObjectIdResponse(id=1917873, encodeId=8398191e8738e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 23 01:04:00 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052365, encodeId=8077205236596, content=<a href='/topic/show?id=aeece1137b' target=_blank style='color:#2F92EE;'>#event#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7113, encryptionId=aeece1137b, topicName=event)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu Jun 21 08:04:00 CST 2018, time=2018-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778433, encodeId=18451e784337e, content=<a href='/topic/show?id=1a7c344897' target=_blank style='color:#2F92EE;'>#biomarkers#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3448, encryptionId=1a7c344897, topicName=biomarkers)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=494139226697, createdName=xzw126, createdTime=Tue Oct 09 16:04:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898700, encodeId=1e601898e0056, content=<a href='/topic/show?id=1fa568e6ec' target=_blank style='color:#2F92EE;'>#epidemiology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6876, encryptionId=1fa568e6ec, topicName=epidemiology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sun Mar 11 00:04:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878248, encodeId=737b18e82489e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat May 19 17:04:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907379, encodeId=fb56190e379e3, content=<a href='/topic/show?id=835e11305d7' target=_blank style='color:#2F92EE;'>#marker#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11305, encryptionId=835e11305d7, topicName=marker)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Sun Jun 24 14:04:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061705, encodeId=65092061e0565, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Mar 02 23:04:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007814, encodeId=c019200e81437, content=<a href='/topic/show?id=421d14663a6' target=_blank style='color:#2F92EE;'>#prevention#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14663, encryptionId=421d14663a6, topicName=prevention)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Nov 28 19:04:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413463, encodeId=f38214134636b, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Wed Jan 17 05:04:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601429, encodeId=2c2a16014290c, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Wed Jan 17 05:04:00 CST 2018, time=2018-01-17, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1917873, encodeId=8398191e8738e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 23 01:04:00 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052365, encodeId=8077205236596, content=<a href='/topic/show?id=aeece1137b' target=_blank style='color:#2F92EE;'>#event#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7113, encryptionId=aeece1137b, topicName=event)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu Jun 21 08:04:00 CST 2018, time=2018-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778433, encodeId=18451e784337e, content=<a href='/topic/show?id=1a7c344897' target=_blank style='color:#2F92EE;'>#biomarkers#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3448, encryptionId=1a7c344897, topicName=biomarkers)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=494139226697, createdName=xzw126, createdTime=Tue Oct 09 16:04:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898700, encodeId=1e601898e0056, content=<a href='/topic/show?id=1fa568e6ec' target=_blank style='color:#2F92EE;'>#epidemiology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6876, encryptionId=1fa568e6ec, topicName=epidemiology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sun Mar 11 00:04:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878248, encodeId=737b18e82489e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat May 19 17:04:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907379, encodeId=fb56190e379e3, content=<a href='/topic/show?id=835e11305d7' target=_blank style='color:#2F92EE;'>#marker#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11305, encryptionId=835e11305d7, topicName=marker)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Sun Jun 24 14:04:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061705, encodeId=65092061e0565, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Mar 02 23:04:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007814, encodeId=c019200e81437, content=<a href='/topic/show?id=421d14663a6' target=_blank style='color:#2F92EE;'>#prevention#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14663, encryptionId=421d14663a6, topicName=prevention)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Nov 28 19:04:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413463, encodeId=f38214134636b, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Wed Jan 17 05:04:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601429, encodeId=2c2a16014290c, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Wed Jan 17 05:04:00 CST 2018, time=2018-01-17, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1917873, encodeId=8398191e8738e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Apr 23 01:04:00 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052365, encodeId=8077205236596, content=<a href='/topic/show?id=aeece1137b' target=_blank style='color:#2F92EE;'>#event#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7113, encryptionId=aeece1137b, topicName=event)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu Jun 21 08:04:00 CST 2018, time=2018-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778433, encodeId=18451e784337e, content=<a href='/topic/show?id=1a7c344897' target=_blank style='color:#2F92EE;'>#biomarkers#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3448, encryptionId=1a7c344897, topicName=biomarkers)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=494139226697, createdName=xzw126, createdTime=Tue Oct 09 16:04:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898700, encodeId=1e601898e0056, content=<a href='/topic/show?id=1fa568e6ec' target=_blank style='color:#2F92EE;'>#epidemiology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6876, encryptionId=1fa568e6ec, topicName=epidemiology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sun Mar 11 00:04:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878248, encodeId=737b18e82489e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat May 19 17:04:00 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907379, encodeId=fb56190e379e3, content=<a href='/topic/show?id=835e11305d7' target=_blank style='color:#2F92EE;'>#marker#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11305, encryptionId=835e11305d7, topicName=marker)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Sun Jun 24 14:04:00 CST 2018, time=2018-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061705, encodeId=65092061e0565, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Mar 02 23:04:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007814, encodeId=c019200e81437, content=<a href='/topic/show?id=421d14663a6' target=_blank style='color:#2F92EE;'>#prevention#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14663, encryptionId=421d14663a6, topicName=prevention)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Nov 28 19:04:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413463, encodeId=f38214134636b, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Wed Jan 17 05:04:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601429, encodeId=2c2a16014290c, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Wed Jan 17 05:04:00 CST 2018, time=2018-01-17, status=1, ipAttribution=)]
    2018-01-17 lq0307

相关资讯

J Hypertens:轮班工作和夜班状态与高血压的关系!

基于这项荟萃分析的结果,轮班工作状态可能在高血压中发挥着重要的作用,因为轮班工作和高血压之间存在显著相关性。然而,夜班状况及高血压风险之间无明显的相关性。

夜班,大概是我们每个医务人员心中的痛

夜班,大概是我们每个医务人员心中的痛,据不完全统计,每个医护一周至少一次上夜班加一次下夜班,而且,你以为夜班之后可以好好休息?真是图样图森破,你还要趁着夜休的时间跑到医院考试、开会、应对检查、处理自己平时完不成的工作。。。。。。所以,如果你能约出去刚值完夜班的医护朋友,听我的,一定要加倍珍惜他!因为你在他心中的地位一定是比你想象的还要重要,不然,他也不会不要命的去赴约。

夜班可能致癌,怕有什么办法?

1.增加心脏病和脑卒中风险发表于BMJ一项对200万人进行的研究表明,轮班工作会增加24%的冠脉事件发生风险,23%的心脏病发作风险,和5%的脑卒中发生风险。尤其是值夜班者,冠脉事件风险高达41%。2.可能致癌夜班可能致癌的原因1、夜班导致抑制肿瘤产生的褪黑激素分泌减少;夜班打乱了人体正常的生物钟,本来应该睡觉的时候却在工作,而人体内能抑制肿瘤产生的褪黑激素一般在夜间分泌,灯光会抑制褪黑激素分泌。

Occup Environ Med:潜心探究13年,终于发现夜班导致受损DNA修复大幅降低,或增加癌症风险:临床大发现

最近,Fred Hutch癌症研究中心的 Parveen Bhatti教授团队在BMJ子刊《职业与环境医学》上发表了一项研究成果。Bhatti教授发现,相比于晚上睡觉的人,晚上工作的人DNA损伤的修复程度非常低,仅是晚上睡觉的人的20%左右。这意味着,长此以往,晚上工作的人体内的DNA损伤会越积越多,患癌症等疾病的风险大大提升。

Obes Rev:经常值夜班,小心变成“苹果型”身材

我国香港学者进行的一项Meta分析发现,倒班工作者,尤其是长期值夜班者,更容易超重或肥胖,而且常常为腹型肥胖,也就是变成“苹果型”身材。

原来医生的夜生活是这样……

忙碌的夜班是每个医生不能说的痛经历着医生成长的必修项我们最大的心愿就是夜间安静下夜班顺利然后好好修护身体.然鹅?!下夜班的故事通常是这样的......... 每次夜班后我的颜值掉线20分体力掉线15分精神掉线15分......每次夜班前都做了一堆计划下夜班之后要去装扮自己内心狂呼“打扮之后我就是最帅的or最美的”而结果通常是......已经疲惫虚弱到只想好好休息夜班前想好要犒劳自己为自己